Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 11, 2006. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing changes in beneficial interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The material change reported is the acquisition of beneficial interests by two individuals:
- Mr. R Bondy acquired 1 Ordinary Share on July 7, 2006, at GBP 15.32 under a Personal Equity Plan.
- Mr. J Clarke acquired 1 Ordinary Share on July 7, 2006, at GBP 15.32 under a Personal Equity Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific share transactions mentioned above in accordance with Disclosure Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of GBP 15.32 against market data for July 7, 2006.
- Confirm the identities of Mr. R Bondy and Mr. J Clarke as directors or persons discharging managerial responsibility.
- Note that this filing contains no financial performance updates for the period.